EUVIMEDEUVIMED entdecken
FallberichtLeserbriefOpen Access

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy

Christopher A Eide, Diana Brewer, Tao Xie, Anna Reister Schultz, Samantha L Savage, Serena Muratcioglu, Noah Merz, Richard D Press, Thomas O'Hare, Thomas Jacob, Tania Q Vu, Cristina E Tognon und 4 weitere

Cancer Cell · 2024

DOI: 10.1016/j.ccell.2024.08.004 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Cell, 2024. Verfasst von Christopher A Eide und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. Hauptthemen laut MEDLINE: Pyridazines, Fusion Proteins, bcr-abl, Imidazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridazinesFusion Proteins, bcr-ablImidazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDrug Resistance, NeoplasmMutationProtein Kinase InhibitorsHumansAntineoplastic Combined Chemotherapy ProtocolsMaleFemaleNiacinamidePyrazoles

Substanzen

PyridazinesponatinibasciminibFusion Proteins, bcr-ablImidazolesProtein Kinase InhibitorsBCR-ABL1 fusion protein, humanNiacinamidePyrazoles

Autor:innen und Institutionen

  • Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Department of Pathology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA.
  • Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Institute of General Medical Sciences
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Eide, C. A., Brewer, D., Xie, T., Schultz, A. R., Savage, S. L., Muratcioglu, S., Merz, N., Press, R. D., O'Hare, T., Jacob, T., Vu, T. Q., Tognon, C. E., Macey, T. A., Kuriyan, J., Kalodimos, C. G., & Druker, B. J. (2024). Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy. Cancer Cell. https://doi.org/10.1016/j.ccell.2024.08.004

Vancouver

Eide CA, Brewer D, Xie T, Schultz AR, Savage SL, Muratcioglu S, et al. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy. Cancer Cell. 2024. doi:10.1016/j.ccell.2024.08.004

BibTeX
@article{Eide2024,
  author = {Eide, Christopher A and Brewer, Diana and Xie, Tao and Schultz, Anna Reister and Savage, Samantha L and Muratcioglu, Serena and Merz, Noah and Press, Richard D and O'Hare, Thomas and Jacob, Thomas and Vu, Tania Q and Tognon, Cristina E and Macey, Tara A and Kuriyan, John and Kalodimos, Charalampos G and Druker, Brian J},
  title = {Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy},
  journal = {Cancer Cell},
  year = {2024},
  doi = {10.1016/j.ccell.2024.08.004}
}
Kostenlos starten →